Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gastric cancer – still many questions to be solved

Gastric cancer – still many questions to be solved Gastric cancer is the fourth most common malignant tumour and the second-most common cause of cancer-related death worldwide. Multidisciplinary care and stage-specific treatment lead to improvements of this very aggressive disease. Accurate staging should include high-resolution computed tomography. Localised disease should also be staged with endoscopic ultrasound. In mucosal gastric cancer, endoscopic resection can replace surgical resection if specific criteria are present. In cancer infiltrating the submucosal layer or beyond, surgical resection including resection of the D2 lymph nodes is regarded as standard of care. In the stages II and III, perioperative chemotherapy has been studied with positive results. In the metastatic setting, treatment goals are palliative. Chemotherapy can prolong survival, improve symptoms and can maintain a better quality of life. Combination chemotherapy including a platinum compound and a fluoropyrimidine is the current standard. 22% of gastric cancers exhibit overexpression of the growth factor receptor Her2. Trastuzumab is a monoclonal antibody directed against Her2 and has shown to prolong survival when combined with cisplatin and fluoropyrimidines in the treatment of Her2-positive gastric cancer. The current role of other biologically targeted therapies like anti-EGFR directed treatment still needs to be established. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Gastric cancer – still many questions to be solved

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/gastric-cancer-still-many-questions-to-be-solved-x7zO5HyFb3
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0267-2
Publisher site
See Article on Publisher Site

Abstract

Gastric cancer is the fourth most common malignant tumour and the second-most common cause of cancer-related death worldwide. Multidisciplinary care and stage-specific treatment lead to improvements of this very aggressive disease. Accurate staging should include high-resolution computed tomography. Localised disease should also be staged with endoscopic ultrasound. In mucosal gastric cancer, endoscopic resection can replace surgical resection if specific criteria are present. In cancer infiltrating the submucosal layer or beyond, surgical resection including resection of the D2 lymph nodes is regarded as standard of care. In the stages II and III, perioperative chemotherapy has been studied with positive results. In the metastatic setting, treatment goals are palliative. Chemotherapy can prolong survival, improve symptoms and can maintain a better quality of life. Combination chemotherapy including a platinum compound and a fluoropyrimidine is the current standard. 22% of gastric cancers exhibit overexpression of the growth factor receptor Her2. Trastuzumab is a monoclonal antibody directed against Her2 and has shown to prolong survival when combined with cisplatin and fluoropyrimidines in the treatment of Her2-positive gastric cancer. The current role of other biologically targeted therapies like anti-EGFR directed treatment still needs to be established.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 30, 2011

References

  • Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world
    Kamangar, F; Dores, GM; Anderson, WF
  • Radiologische Bildgebung des oberen Gastrointestinaltraktes, Teil II Magen
    Grenacher, L; Hansmann, J
  • Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography
    Hwang, SW; Lee, DH; Lee, SH
  • Imaging in local staging of gastric cancer: a systematic review
    Kwee, RM; Kwee, TC
  • How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review
    Puli, SR; Batapati Krishna Reddy, J; Bechtold, ML
  • Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer
    van Westreenen, HL; Westerterp, M; Bossuyt, PM
  • Pretherapeutic laparoscopic staging in advanced gastric carcinoma
    Feussner, H; Omote, K; Fink, U
  • Lymphadenectomy for gastric adenocarcinoma: should west meet east?
    Yoon, SS; Yang, HK
  • Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
    Songun, I; Putter, H; Kranenbarg, EM; Sasako, M; van de Velde, CJ
  • Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial
    Boige, V; Pignon, JP; Saint-Aubert, B
  • Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    Cunningham, D; Allum, WH; Stenning, SP
  • Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954
    Schuhmacher, C; Gretschel, S; Lordick, F
  • Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
    Sakuramoto, S; Sasako, M; Yamaguchi, T
  • Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis
    Paoletti, X; Oba, K
  • Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
    Macdonald, JS; Smalley, SR; Benedetti, J
  • Patterns of initial recurrence in completely resected gastric adenocarcinoma
    D'Angelica, M; Gonen, M; Brennan, MF
  • Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology
    Rosen, HR; Jatzko, G; Repse, S
  • A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer
    Yan, TD; Black, D; Sugarbaker, PH
  • Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group
    Ajani, JA; Moiseyenko, VM; Tjulandin, S
  • Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    Cunningham, D; Allum, WH; Stenning, SP
  • Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft internistische onkologie
    Al-Batran, SE; Hartmann, JT; Probst, S
  • Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    Kang, YK; Kang, WK; Shin, DB
  • Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group
    Van Cutsem, E; Moiseyenko, VM; Tjulandin, S
  • Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial
    Lorenzen, S; Hentrich, M; Haberl, C
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial
    Bang, YJ; Van Cutsem, E; Feyereislova, A
  • HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
    Rüschoff, J; Dietel, M; Baretton, G
  • AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
    Kang, Y; Ohtsu, A; Van Cutsem, E
  • The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
    Heiss, MM; Murawa, P; Koralewski, P